DNA RNA and Cells
22 January 2025
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA321920 January 2025
CARsgen’s Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial15 January 2025
Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company15 January 2025
Chromatin Bioscience’s synthetic promoter supports EsoBiotec’s ESO-T01 CAR-T therapy as it enters the clinic14 January 2025
Keylicon Biosciences Secures Exclusive Rights to Modified Self-Amplifying RNA Technology14 January 2025
Ex-Deep Genomics, Moderna Execs Get Backing Led by Gradient to Develop Next-Generation mRNA Therapeutics with AI14 January 2025
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases13 January 2025
CARsgen’s Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial11 January 2025
Verismo Therapeutics Announces First Patient Infused in Phase 1 CELESTIAL-301 Clinical Trial of SynKIR™-310News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports